BACKGROUND: Millions of patients present annually with chest pain, but only 10% have myocardial infarction (MI). We recently reported comparative sensitivity and specificity of available markers in the diagnosis of MI; however, optimum interpretation of marker results requires prognostic follow-up data. HYPOTHESIS: The study was undertaken to study the accuracy of CK-MB subforms, troponin I and T, myoglobin, and CK-MB in predicting clinical events at 30 days and 6 months. METHODS: In all, 955 consecutive patients with chest pain were enrolled in a prospective, multicenter, double-blind study to test the prognostic accuracy of these markers. RESULTS:Myocardial infarction was diagnosed in 119 by CK-MB mass criteria and unstable angina (UA) in 203 patients by clinical criteria. Follow-up at 30 days and 6 months was available in 824 and 724 patients, respectively, with mortalities of 2.8 and 4.14%, respectively. Cumulative 6-month mortality was 5.6% in MI, 4.4% in UA, and 3.0% in others. Revascularization was reported in 9.3% of patients by 6 months. A positive test on each of the markers except myoglobin was predictive of revascularization. The composite endpoint of death or revascularization occurred in 107 patients by 6 months and a positive result on each of the markers was predictive of this composite endpoint (p < 0.05). The relative risk of death or revascularization for patients who did not have MI but tested positive on each of the markers was > 1.0 but did not reach statistical significance. CONCLUSIONS: With the possible exception of myoglobin, each of the diagnostic markers displayed similar prognostic performance in patients with chest pain presenting to emergency departments. The most appropriate markers to triage patients with chest pain, which has both adequate early diagnostic sensitivity and prognostic accuracy, are the CK-MB subforms.
RCT Entities:
BACKGROUND: Millions of patients present annually with chest pain, but only 10% have myocardial infarction (MI). We recently reported comparative sensitivity and specificity of available markers in the diagnosis of MI; however, optimum interpretation of marker results requires prognostic follow-up data. HYPOTHESIS: The study was undertaken to study the accuracy of CK-MB subforms, troponin I and T, myoglobin, and CK-MB in predicting clinical events at 30 days and 6 months. METHODS: In all, 955 consecutive patients with chest pain were enrolled in a prospective, multicenter, double-blind study to test the prognostic accuracy of these markers. RESULTS:Myocardial infarction was diagnosed in 119 by CK-MB mass criteria and unstable angina (UA) in 203 patients by clinical criteria. Follow-up at 30 days and 6 months was available in 824 and 724 patients, respectively, with mortalities of 2.8 and 4.14%, respectively. Cumulative 6-month mortality was 5.6% in MI, 4.4% in UA, and 3.0% in others. Revascularization was reported in 9.3% of patients by 6 months. A positive test on each of the markers except myoglobin was predictive of revascularization. The composite endpoint of death or revascularization occurred in 107 patients by 6 months and a positive result on each of the markers was predictive of this composite endpoint (p < 0.05). The relative risk of death or revascularization for patients who did not have MI but tested positive on each of the markers was > 1.0 but did not reach statistical significance. CONCLUSIONS: With the possible exception of myoglobin, each of the diagnostic markers displayed similar prognostic performance in patients with chest pain presenting to emergency departments. The most appropriate markers to triage patients with chest pain, which has both adequate early diagnostic sensitivity and prognostic accuracy, are the CK-MB subforms.
Authors: J Zimmerman; R Fromm; D Meyer; A Boudreaux; C C Wun; R Smalling; B Davis; G Habib; R Roberts Journal: Circulation Date: 1999-04-06 Impact factor: 29.690
Authors: E Braunwald; A Maseri; P W Armstrong; R M Califf; W B Gibler; C W Hamm; M L Simoons; F Van de Werf Journal: Eur Heart J Date: 1998-04 Impact factor: 29.983
Authors: T H Lee; G W Rouan; M C Weisberg; D A Brand; D Acampora; C Stasiulewicz; J Walshon; G Terranova; L Gottlieb; B Goldstein-Wayne Journal: Am J Cardiol Date: 1987-08-01 Impact factor: 2.778
Authors: P R Puleo; D Meyer; C Wathen; C B Tawa; S Wheeler; R J Hamburg; N Ali; S D Obermueller; J F Triana; J L Zimmerman Journal: N Engl J Med Date: 1994-09-01 Impact factor: 91.245
Authors: E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: E M Ohman; P W Armstrong; R H Christenson; C B Granger; H A Katus; C W Hamm; M A O'Hanesian; G S Wagner; N S Kleiman; F E Harrell; R M Califf; E J Topol Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: W E Boden; R A O'Rourke; M H Crawford; A S Blaustein; P C Deedwania; R G Zoble; L F Wexler; R E Kleiger; C J Pepine; D R Ferry; B K Chow; P W Lavori Journal: N Engl J Med Date: 1998-06-18 Impact factor: 91.245
Authors: John T Nagurney; David Frank Brown; Claudia Chae; YuChiao Chang; Won Chung; Hilarie Cranmer; Li Dan; Jonathan Fisher; Shamai Grossman; Usha Tedrow; Kent Lewandrowski; Ik-Kyung Jang Journal: J Thromb Thrombolysis Date: 2005-02 Impact factor: 2.300
Authors: Andreas Sandø; Martin Schultz; Jesper Eugen-Olsen; Lars Simon Rasmussen; Lars Køber; Erik Kjøller; Birgitte Nybo Jensen; Lisbet Ravn; Theis Lange; Kasper Iversen Journal: Scand J Trauma Resusc Emerg Med Date: 2016-08-05 Impact factor: 2.953